Company intelligence / Profile preview

2C Tech

Irvine, California, United Statesmedtechinnovator.org ↗

Ownership: Private
Development stage: Preclinical

Overview

2C Tech has completed an ex-US Phase I clinical trial in Mexico City demonstrating safety and preliminary efficacy of its quantum dot technology for vision restoration in patients with retinitis pigmentosa. The company plans to initiate a US-based Early Feasibility Study under the FDA's EFS program to further evaluate safety and functionality. Results from the initial human study were promising for both safety and potential improvement of vision

Therapeutic areas: EndocrinologyOphthalmology
Modalities: DeviceNanoparticle (Quantum Dot) technology
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

SeeQ

Pre-clinical

Indications: Retinitis pigmentosa, Diabetic retinopathy, Macular degeneration

Partnerships

Hoya Corp.InFocus Capital Partners

Beyond the preview

Go deeper on 2C Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2C Tech.

Explore the full profile